"It also provides us capabilities in gene therapy," he added. "We have a robust internal portfolio of gene therapies in ophthalmology and neuroscience in Novartis Institutes for Biomedical Research. And we look forward to using AveXis's capabilities and technical development capabilities to be able to advance that portfolio. "Our goal is to continue to build on our core medicines," he said. "AveXis is also developing gene therapy candidates in Rett Syndrome and inherited amyotrophic lateral sclerosis (ALS).

Source: The Star April 09, 2018 08:48 UTC